NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said after the close of the market Tuesday that it intends to offer 10 million shares of its common stock in an underwritten public offering.

Leerink Partners and Cantor Fitzgerald are acting as joint book-running managers for the offering, and LifeSci Capital is acting as co-manager. HTG expects to grant the underwriters a 30-day option to purchase up to an additional 1.5 million shares of its stock.

The shares are being offered by HTG pursuant to a shelf registration statement filed by the company in April 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.